Vimarsana
Biggest News Aggregation in the World

Page 2 - Axi Cel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Axi Cel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Axi Cel Today - Breaking & Trending Today

Bridging RT Before CAR T-Cell Therapy Can Benefit Patients With R/R DLBCL - Vimarsana News

Bridging RT Before CAR T-Cell Therapy Can Benefit Patients With R/R DLBCL

Researchers found that patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) may benefit from bridging radiation therapy (RT) ahead of receiving chimeric antigen receptor (CAR) T-cell therapy.

Source: ajmc.com
Axi-Cel Yields High Responses in R/R High-Risk Large B-Cell Lymphoma - Vimarsana News

Axi-Cel Yields High Responses in R/R High-Risk Large B-Cell Lymphoma

Findings from the phase 2 ALYCANTE trial support axicabtagene ciloleucel as a second-line treatment for patients with relapsed/refractory (R/R) large B-cell lymphoma who are ineligible to undergo a transplant.

Source: ajmc.com
Axi-Cel Extends Survival vs Standard of Care for R/R LBCL - Vimarsana News

Axi-Cel Extends Survival vs Standard of Care for R/R LBCL

An overall survival (OS analysis of the phase 3 ZUMA-7 trial demonstrated longer OS in patients treated with axicabtagene ciloleucel (axi-cel) vs the standard of care for early relapsed or refractory (R/R) large B-cell lymphoma (LBCL).

Source: ajmc.com
ZUMA-23: A Global, Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel Versus Standard-of-Care as First-Line Therapy in Patients With High-Risk Large B-Cell Lymphoma - Vimarsana News

ZUMA-23: A Global, Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel Versus Standard-of-Care as First-Line Therapy in Patients With High-Risk Large B-Cell Lymphoma

Jason R. Westin, MD, MS, FACP, reviews the background and study design of ZUMA-23, the first Phase III, randomized controlled study to evaluate CAR T-cell therapy as a first-line regimen in patients with high-risk LBCL.

Axi-Cel Shows Favorable Safety, Efficacy in Real-World Study of Early FL Outcomes - Vimarsana News

Axi-Cel Shows Favorable Safety, Efficacy in Real-World Study of Early FL Outcomes

The autologous CAR T-cell therapy axicabtagene ciloleucel (axi-cel) demonstrated effectiveness and safety consistent with the ZUMA-5 trial when used in real-world settings to treat a broader population of patients with follicular lymphoma (FL).

Source: ajmc.com